X1 Biotech raised $0.24 million to advance the development of its first-in-class small-molecule RUNX1 inhibitor X101 for the treatment of vascular and fibrotic diseases, including CADASIL and pulmonary fibrosis, both rare disorders
X1 Biotech raised $0.24 million to advance the development of its first-in-class small-molecule RUNX1 inhibitor X101 for the treatment of vascular and fibrotic diseases, including CADASIL and pulmonary fibrosis, both rare disorders